Peter Graham

ORCID: 0000-0002-4957-4895 · 2 papers in corpus
2019
Theranostics ·doi:10.7150/thno.34692

The current biomarkers available in the clinic are not enough for early diagnosis or for monitoring disease progression of ovarian cancer. Liquid biopsy is a minimally invasive test and has the advantage of early diagnosis and real-time mon…

article 2014
·doi:10.4172/2161-0932.1000235

Uterine endometrialpolyp, hyperplasia and malignant transformation are well known side effects of Tamoxifen use in breast cancer patients. We present a case of hydronephrosis secondary to extra-uterine endometriosis in a female with mixed I…